Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.58 |
| ▸ | CCR8 | P51685 | 1/20 | 0.58 |
| ▸ | METAP2 | P50579 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 9/20 | 0.39 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20019709 | 0.85 | PARP1 (0.44) | CCR1CCR8PARP1KDM4CADORA2A | |
| SCHEMBL13831067 | 0.85 | CCR1 (0.41) | CCR1CCR8METAP2CYP2A6NOS3 | |
| SCHEMBL3992598 | 0.83 | CCR1 (0.47) | CCR1CCR8METAP2CYP2A6TGFBR1 | |
| SCHEMBL310731 | 0.79 | CCR1 (0.50) | CCR1CCR8METAP2CYP2A6TGFBR1 | |
| SCHEMBL17708555 | 0.77 | ADORA2A (0.39) | CCR1CCR8NOS3NOS2PARP1 | |
| SCHEMBL3745071 | 0.75 | CCR1 (0.62) | CCR1CCR8METAP2CYP2A6TGFBR1 | |
| SCHEMBL1456972 | 0.75 | CCR1 (0.62) | CCR1CCR8METAP2CYP2A6TGFBR1 | |
| SCHEMBL196966 | 0.75 | CCR1 (1.00) | CCR1CCR8METAP2CYP2A6TGFBR1 | |
| SCHEMBL30511194 | 0.75 | CCR1 (1.00) | CCR1CCR8METAP2CYP2A6TGFBR1 | |
| SCHEMBL29388304 | 0.75 | CCR1 (1.00) | CCR1CCR8METAP2CYP2A6TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2023-02-21 | — | — | US | disclosed |
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD (CN) | 2021-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032241-A1 | AROMATIC HETEROCYCLIC COMPOUND, INTERMEDIATE THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, NOTUM, WEE1 | CCR1 1379/4885CCR8 607/4885METAP2 2685/4885 |
| US-11584745-B2 | Aromatic heterocyclic compound, intermediate thereof, preparation method therefor, and pharmaceutical composition and use thereof | ALK, NOTUM, WEE1 | CCR1 1379/4885CCR8 607/4885METAP2 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.